Chronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases , Phoenix, Arizona.
Division of Nephrology and Hypertension, University of Louisville , Louisville, Kentucky.
Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1484-F1492. doi: 10.1152/ajprenal.00183.2018. Epub 2018 Aug 22.
We examined the association of urine inositol 1,3,4,5,6-pentakisphosphate 2-kinase (IPP2K) with the presence and progression of diabetic kidney disease (DKD) lesions. Urine IPP2K was measured at baseline by quantitative liquid chromatography-mass spectrometry in 215 participants from the Renin-Angiotensin System Study who had type 1 diabetes and were normoalbuminuric and normotensive with normal or increased glomerular filtration rate (GFR). Urine IPP2K was detectable in 166 participants. Participants with IPP2K below the limit of quantification (LOQ) were assigned concentrations of LOQ/√2. All concentrations were then standardized to urine creatinine (Cr) concentration. Kidney morphometric data were available from biopsies at baseline and after 5 yr. Relationships of IPP2K/Cr with morphometric variables were assessed by linear regression after adjustment for age, sex, diabetes duration, hemoglobin A, mean arterial pressure, treatment assignment, and, for longitudinal analyses, baseline structure. Baseline mean age was 29.7 yr, mean diabetes duration 11.2 yr, median albumin excretion rate 5.0 μg/min, and mean iohexol GFR 129 ml·min·1.73m. Higher IPP2K/Cr was associated with higher baseline peripheral glomerular total filtration surface density [Sv(PGBM/glom), tertile 3 vs. tertile 1 β = 0.527, P = 0.011] and with greater preservation of Sv(PGBM/glom) after 5 yr ( tertile 3 vs. tertile 1 β = 0.317, P = 0.013). Smaller increases in mesangial fractional volume ( tertile 3 vs. tertile 1 β = -0.578, P = 0.018) were observed after 5 yr in men with higher urine IPP2K/Cr concentrations. Higher urine IPP2K/Cr is associated with less severe kidney lesions at baseline and with preservation of kidney structure over 5 yr in individuals with type 1 diabetes and no clinical evidence of DKD at baseline.
我们研究了尿肌醇 1,3,4,5,6-五磷酸 2-激酶(IPP2K)与糖尿病肾病(DKD)病变的存在和进展的关系。在 215 名患有 1 型糖尿病且正常白蛋白尿和正常血压、正常或增加的肾小球滤过率(GFR)的肾素-血管紧张素系统研究参与者中,通过定量液相色谱-质谱法在基线时测量尿 IPP2K。在 166 名参与者中可检测到尿 IPP2K。将低于定量下限(LOQ)的参与者的浓度分配给 LOQ/√2。所有浓度均标准化为尿肌酐(Cr)浓度。基线时和 5 年后均可获得肾脏形态计量学数据。在调整年龄、性别、糖尿病病程、血红蛋白 A、平均动脉压、治疗分配以及纵向分析中的基线结构后,通过线性回归评估 IPP2K/Cr 与形态计量学变量的关系。基线时的平均年龄为 29.7 岁,平均糖尿病病程为 11.2 年,中位白蛋白排泄率为 5.0μg/min,碘海醇估计的肾小球滤过率为 129ml·min·1.73m。较高的 IPP2K/Cr 与较高的基线外周肾小球总滤过表面积密度[Sv(PGBM/glom),三分位 3 与三分位 1β=0.527,P=0.011]和 5 年后 Sv(PGBM/glom)的更大保留相关(三分位 3 与三分位 1β=0.317,P=0.013)。在 5 年后,较高尿 IPP2K/Cr 浓度的男性中观察到系膜体积分数的较小增加(三分位 3 与三分位 1β=-0.578,P=0.018)。在基线时没有 DKD 临床证据的 1 型糖尿病个体中,较高的尿 IPP2K/Cr 与更严重的肾脏病变相关,与 5 年内肾脏结构的保留相关。